|
 |
| Seegene specializes in molecular diagnostics and develops technology and products that diagnose disease from the genetic level. Established in 2000, Seegene has released various molecular diagnosis products that are developed in-house including world-class simultaneous and multiple detection technologies (ACP™, DPO™, READ, TOCE™). |
| Seegene's creative and innovative simultaneous and multiple detection technology leaps ahead of current technology and allows testing of multiple of pathogens with one single test, minimizing testing time and cost when compared to conventional testing methods that evaluate one pathogen per test. |
| Seegene's molecular diagnosis technology and products allow patients to benefit from cost effective and personalized diagnosis tools and allow doctors to offer accurate and effective treatment to patients. Also, the technology enhances current issues with genetic diagnosis, allowing strategic alliance opportunities with global health care companies and large health examination centers. |
 |
 |
 |
| Seegene boasts remarkable results and profit, which is rare among Korea's biotech venture companies. Developed with specialized skills and know-how that have been accumulated over the years, our products have been touted as superior in multiplex testing efficiency and cost effectiveness for infectious diseases such as respiratory virus, sexually transmitted diseases, human papilloma virus, tuberculosis and drug-resistant tuberculosis, and hepatitis. These products are widely used in over 100 hospitals and clinical laboratories in Korea and exported to more than 375 institutions in over 52 countries globally. |
 |
Molecular diagnostics is an in vitro diagnostic tool for analyzing genes to determine the existence of disease. Introduced in the late 1990s and early 2000s onto the diagnostics market, molecular diagnostics is a state-of-the-art diagnostic tool that leapfrogs conventional methods such as incubation diagnostics and immunodiagnosis.
 |
|
Molecular diagnostics is the sole diagnosis method which enables early diagnosis and it's accuracy rate is much higher compared to conventional testing methods. Tehrefore it is a "blue ocean" business with a high growth rate (CAGR 17%, 2010-2013).
The global molecular diagnosis market is forecasted to be approximately $6.6B (7 Trillion KRW), and Seegene is looking forward to leading the global molecular diagnosis market with differentiated and superior products. |
| |  |
|
 |
Seegene’s products have been proven superior through various publications from government institutions and laboratories on clinical assessments of product comparison. As of 2012, over 500 Korean and international publications quoted Seegene’s core technologies (the largest among Korean biotech companies) and its products are officially certified by the Canadian government, CE-IVD from Europe, HT from the Ministry of Health and Welfare of Korea, CE certification from Europe and other various certifications. |
|
 |
| Recognized for one of Seegene's flagship diagnostic products that diagnoses 12 respiratory viruses in a single test, the company was selected as the recipient of IR52 Jang Young Shil award, which is considered as the best technology award in the industry, and its products were chosen as "World Class Products" by the Ministry of Knowledge Economy.
We won the Presidential Award, which is the best award in the Technology Innovation category, at the 11th Annual Small to Medium Business Technology Innovation Awards ceremony and was awarded the Venture Business Steel Tower Industrial Medal at 2010 Venture Korea as well. Seegene Inc. has been regarded as examplary company not only for its technical capabilities but also for receiving numerous awards including a Korean Ethical Business Award and Korean CEO Association Award.
|
| Based on superior technology, creative value and leadership, Seegene Inc. Assures that we will take a responsibility to become a role business model to make Korea as the world leader of Molecular Diagnostics. We are looking forward to make a contribution to nations' economic growth by continuously increasing our sales revenue every year. |
|
|
- As this product is Medical Device, please read 'caution' and 'instruction' before use.
- Deliberation number : 2013-I10-01-0810 (Analyzing product, DNA amplification)
|
|
|
